Clinical trial
A Phase 2 Study Evaluating the Efficacy and Safety Agent AUR103 Calcium in Patients With Advanced, Well or Moderately Differentiated Neuroendocrine Tumours (BHARAT-3)
NCT07640737 is registered in ClinicalTrials.gov with Aurigene Discovery Technologies Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study Evaluating the Efficacy and Safety Agent AUR103 Calcium in Patients With Advanced, Well or Moderately Differentiated Neuroendocrine Tumours (BHARAT-3)
- Lead sponsor
- Aurigene Discovery Technologies Limited
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- June 30, 2026
- Completion date
- January 31, 2029
- Enrollment
- 30 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
advanced net of gi origin, neuroendocrine (ne) tumors